Long-term Safety of Rituximab in Primary Sjögren Syndrome: The Experience of a Single Center.

Long-term RTX administration was shown to be a safe, well tolerated, and effective treatment in patients with active systemic disease, significantly reducing ESSDAI and controlling disease activity.